TMAO: a Potential Mediator of Clopidogrel Resistance

Overview

Journal Sci Rep

Specialty Science

Date 2021 Mar 23

PMID 33753834

Citations 9

Authors

Ruisong Ma

Wenwen Fu

Jing Zhang

Xiaorong Hu

Jun Yang

Hong Jiang

Affiliations

Soon will be listed here.

Abstract

Trimethylamine-N-oxide (TMAO) can activate platelets and increase thrombosis risk in clinical and experimental models. Meanwhile, the patients with coronary artery disease have higher serum TMAO level. However, it remains unknown whether Clopidogrel Resistance (CR) could be attributed to TMAO. The present study aimed investigate the effects of TMAO on clopidogrel in ischemia and reperfusion (IR) model in rats. Clopidogrel could (1) promote the production of platelets, induce an increase in the platelet-larger cell ratio; (2) prolong the tail bleeding time; (3) reduce platelet aggregation function, induced by ADP, and alleviate myocardial thrombus burden. TMAO could partially offset the effects of clopidogrel and induce CR. Thus, the present study demonstrated that circulating TMAO could reduce the inhibitory effects of clopidogrel on platelet aggregation. TMAO may be a potential mediator of clopidogrel resistance.

Citing Articles

Efficacy and compatibility mechanism of bear bile powder in Shexiang Tongxin dropping pills for acute myocardial infarction treatment.

Luo Y, Zhang F, Zhu L, Ye J, Pan H, Lu X Chin Med. 2025; 20(1):14.

PMID: 39863867 PMC: 11763157. DOI: 10.1186/s13020-025-01060-x.

Microbiome-Derived Trimethylamine N-Oxide (TMAO) as a Multifaceted Biomarker in Cardiovascular Disease: Challenges and Opportunities.

Jaworska K, Kopacz W, Koper M, Ufnal M Int J Mol Sci. 2024; 25(23).

PMID: 39684223 PMC: 11641139. DOI: 10.3390/ijms252312511.

Gut Microbe-Generated Metabolite Trimethylamine-N-Oxide and Ischemic Stroke.

Li Z, He X, Fang Q, Yin X Biomolecules. 2024; 14(11).

PMID: 39595639 PMC: 11591650. DOI: 10.3390/biom14111463.

Role of Trimethylamine N-Oxide in Heart Failure.

Jing L, Zhang H, Xiang Q, Hu H, Zhai C, Xu S Rev Cardiovasc Med. 2024; 25(7):240.

PMID: 39139438 PMC: 11317343. DOI: 10.31083/j.rcm2507240.

Genetic variability in stroke patients: CYP2C19 polymorphisms unraveled.

Peng P, Xiao Y, Peng X, Chen J, Chen N BMC Med Genomics. 2024; 17(1):109.

PMID: 38671468 PMC: 11055221. DOI: 10.1186/s12920-024-01886-8.

References

Gupta N, Buffa J, Roberts A, Sangwan N, Skye S, Li L . Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease. Arterioscler Thromb Vasc Biol. 2020; 40(5):1239-1255. PMC: 7203662. DOI: 10.1161/ATVBAHA.120.314139. View

Skye S, Zhu W, Romano K, Guo C, Wang Z, Jia X . Microbial Transplantation With Human Gut Commensals Containing CutC Is Sufficient to Transmit Enhanced Platelet Reactivity and Thrombosis Potential. Circ Res. 2018; 123(10):1164-1176. PMC: 6223262. DOI: 10.1161/CIRCRESAHA.118.313142. View

Zhu W, Buffa J, Wang Z, Warrier M, Schugar R, Shih D . Flavin monooxygenase 3, the host hepatic enzyme in the metaorganismal trimethylamine N-oxide-generating pathway, modulates platelet responsiveness and thrombosis risk. J Thromb Haemost. 2018; 16(9):1857-1872. PMC: 6156942. DOI: 10.1111/jth.14234. View

van Mens T, Buller H, Nieuwdorp M . Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: a blueprint for drugging the microbiota in the treatment of cardiometabolic disease?. J Thromb Haemost. 2018; 17(1):3-5. DOI: 10.1111/jth.14331. View

Ruisong M, Xiaorong H, Gangying H, Chunfeng Y, Changjiang Z, Xuefei L . The Protective Role of Interleukin-33 in Myocardial Ischemia and Reperfusion Is Associated with Decreased HMGB1 Expression and Up-Regulation of the P38 MAPK Signaling Pathway. PLoS One. 2015; 10(11):e0143064. PMC: 4646496. DOI: 10.1371/journal.pone.0143064. View

Oliphant C, Trevarrow B, Dobesh P . Clopidogrel Response Variability: Review of the Literature and Practical Considerations. J Pharm Pract. 2015; 29(1):26-34. DOI: 10.1177/0897190015615900. View

Esteve-Pastor M, Ruiz-Nodar J, Orenes-Pinero E, Rivera-Caravaca J, Quintana-Giner M, Veliz-Martinez A . Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. J Cardiovasc Pharmacol Ther. 2017; 23(1):57-65. DOI: 10.1177/1074248417724869. View

Zeisel S, Warrier M . Trimethylamine N-Oxide, the Microbiome, and Heart and Kidney Disease. Annu Rev Nutr. 2017; 37:157-181. DOI: 10.1146/annurev-nutr-071816-064732. View

Gurbel P, Becker R, Mann K, Steinhubl S, Michelson A . Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007; 50(19):1822-34. DOI: 10.1016/j.jacc.2007.07.051. View

10.

Qi J, You T, Li J, Pan T, Xiang L, Han Y . Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J Cell Mol Med. 2017; 22(1):185-194. PMC: 5742728. DOI: 10.1111/jcmm.13307. View

11.

Warlo E, Arnesen H, Seljeflot I . A brief review on resistance to P2Y receptor antagonism in coronary artery disease. Thromb J. 2019; 17:11. PMC: 6558673. DOI: 10.1186/s12959-019-0197-5. View

12.

Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp C . Calcium-channel blockers decrease clopidogrel-mediated platelet inhibition. Heart. 2009; 96(3):186-9. DOI: 10.1136/hrt.2009.171488. View

13.

Grosdidier C, Quilici J, Loosveld M, Camoin L, Moro P, Saut N . Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications. Am J Cardiol. 2013; 111(7):985-90. DOI: 10.1016/j.amjcard.2012.12.013. View

14.

Yun S, Sim E, Goh R, Park J, Han J . Platelet Activation: The Mechanisms and Potential Biomarkers. Biomed Res Int. 2016; 2016:9060143. PMC: 4925965. DOI: 10.1155/2016/9060143. View

15.

Schiattarella G, Sannino A, Esposito G, Perrino C . Diagnostics and therapeutic implications of gut microbiota alterations in cardiometabolic diseases. Trends Cardiovasc Med. 2018; 29(3):141-147. DOI: 10.1016/j.tcm.2018.08.003. View

16.

Trenk D, Hochholzer W . Genetics of platelet inhibitor treatment. Br J Clin Pharmacol. 2013; 77(4):642-53. PMC: 3971981. DOI: 10.1111/bcp.12230. View

17.

Katoh M, Nakajima M, Shimada N, Yamazaki H, Yokoi T . Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000; 55(11-12):843-52. DOI: 10.1007/s002280050706. View

18.

Lakkis N, Dokainish H, Abuzahra M, Tsyboulev V, Jorgensen J, De Leon A . Reticulated platelets in acute coronary syndrome: a marker of platelet activity. J Am Coll Cardiol. 2004; 44(10):2091-3. DOI: 10.1016/j.jacc.2004.05.033. View

19.

Cesari F, Marcucci R, Gori A, Caporale R, Fanelli A, Casola G . Reticulated platelets predict cardiovascular death in acute coronary syndrome patients. Insights from the AMI-Florence 2 Study. Thromb Haemost. 2013; 109(5):846-53. DOI: 10.1160/TH12-09-0709. View

20.

Valgimigli M, Bueno H, Byrne R, Collet J, Costa F, Jeppsson A . 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the.... Eur Heart J. 2017; 39(3):213-260. DOI: 10.1093/eurheartj/ehx419. View